The current treatment landscape: The need for antifungal stewardship programmes

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue , 2016, Pages ii5-ii12

  Muñoz, Patricia ^a,b,c,d   Bouza, Emilioon ^a,b,c,d   Alonso, Roberto ^a   Anaya, Fernando ^a   Banares, Rafael ^a   Bustinza, Amaya ^a   Cáliz, Betsabé ^a   Fernández Cruz, Ana ^a   Escribano, Pilar ^a   Fernández Quero, Lorenzo ^a   Frias, Isabel ^a   Gayoso, Jorge ^a   Gijón, Paloma ^a   Guinea, Jesús ^a   Hortal, Javier ^a   Martínez, Maria del Carmen ^a   Márquez, Iván ^a   Padilla, Belén ^a   Peláez, Teresa ^a   Peral, José ^a   Pinilla, Blanca ^a   Rodríguez, Carmen Guadalupe ^a   Salcedo, Magdalena ^a   Sánchez, Carlos ^a   Sánchez Somolinos, Mar ^a   Sanjurjo, Maria ^a   Serrano, David ^a   Valerio, Maricela ^a   Vena, Antonio ^a   Verde, Eduardo ^a   Vilalta, Encarnación ^a   Zamora, Elena ^a   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL STEWARDSHIP PROGRAM; ANTIFUNGAL THERAPY; ARTICLE; COOPERATION; COST EFFECTIVENESS ANALYSIS; DRUG MISUSE; ELECTRONIC PRESCRIBING; GENERAL HOSPITAL; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; LEADERSHIP; PRACTICE GUIDELINE; CLINICAL PRACTICE; COST; ECONOMICS; INAPPROPRIATE PRESCRIBING; MYCOSES; OFF LABEL DRUG USE; STATISTICS AND NUMERICAL DATA;

ANTIFUNGAL AGENTS; COSTS AND COST ANALYSIS; HUMANS; INAPPROPRIATE PRESCRIBING; MYCOSES; OFF-LABEL USE; PRACTICE PATTERNS, PHYSICIANS'; QUALITY OF HEALTH CARE;

EID: 84994784157     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw391     Document Type: Article

References (56)

1. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012; 25: 107-15.
2. Andes D, Azie N, Yang H et al. Drug-drug interaction associated with mold-active triazoles among hospitalized patients. Antimicrob Agents Chemother 2016; 60: 3398-406.
3. Valerio M, Rodriguez-Gonzalez CG, Munoz P et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69: 1993-9.
4. AitkenSL, BeydaND, ShahDN, et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother 2014; 48: 683-90.
5. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
6. Ostrosky-Zeichner L. Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med 2004; 32: 2552-3.
7. Gonzalez de Molina FJ, Leon C, Ruiz-Santana S et al. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care 2012; 16: R105.
8. Ostrosky-Zeichner L, Shoham S, Vazquez J et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 2014; 58: 1219-26.
9. Pile JC. Antimicrobial stewardship: optimizing antibiotic use in an era of increasing resistance and rising costs. J Hosp Med 2011; 6 Suppl 1: S1-3.
10. Nivoix Y, Launoy A, Lutun P et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother 2012; 67: 2506-13.
11. Sutepvarnon A, Apisarnthanarak A, Camins B et al. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol 2008; 29: 370-3.
12. Singh N, Wagener MM, Cacciarelli TV et al. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426-31.
13. Munoz P, Rojas L, Cervera C et al. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transplant 2012; 26: 87-96.
14. San-Juan R, Aguado JM, Lumbreras C et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 2011; 92: 346-50.
15. Valerio M, Munoz P, Rodriguez-Gonzalez C et al. Training should be the first step toward an antifungal stewardship program. Enferm Infecc Microbiol Clin 2015; 33: 221-7.
16. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322-7.
17. Swoboda S, Lichtenstern C, Ober MC et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009; 55: 418-24.
18. Guarascio AJ, Slain D, McKnight R et al. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2013; 35: 145-8.
19. Howard P, Pulcini C, Levy Hara G et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother 2015; 70: 1245-55.
20. Munoz P, Valerio M, Vena A et al. Antifungal stewardship in daily practice and health economic implications. Mycoses 2015; 58 Suppl 2: 14-25.
21. StandifordHC, Chan S, TripoliM, et al. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012; 33: 338-45.
22. Cappelletty D, Jacobs D. Evaluating the impact of a pharmacist's absence from an antimicrobial stewardship team. Am J Health Syst Pharm 2013; 70: 1065-9.
23. Agrawal S, Barnes R, Brüggemann R. The role of the multidisciplinary team in antifungal stewardship. J Antimicrob Chemother 2016; 71 Suppl 2: ii37-ii42.
24. Lopez-Medrano F, San Juan R, Lizasoain M et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19: 56-61.
25. Valerio M, Munoz P, Rodriguez CG et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect 2015; 21: 492:e1-9.
26. Barlam TF, Cosgrove SE, Abbo LM et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62: e51-77.
27. Cook PP, Catrou PG, Christie JD et al. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004; 53: 853-9.
28. Apisarnthanarak A, Yatrasert A, Mundy LM et al. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010; 31: 722-7.
29. Mondain V, Lieutier F, Hasseine L et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection 2013; 41: 621-8.
30. Antworth A, Collins CD, Kunapuli A et al. Impact of an antimicrobial stewardship programcomprehensive care bundle on management of candidemia. Pharmacotherapy 2013; 33: 137-43.
31. Charani E, Castro-Sanchez E, Sevdalis N et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of "prescribing etiquette". Clin Infect Dis 2013; 57: 188-96.
32. Charani E, Castro-Sanchez E, Holmes A. The role of behavior change in antimicrobial stewardship. Infect Dis Clin North Am 2014; 28: 169-75.
33. Valerio M, Vena A, Bouza E et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis 2015; 15: 80.
34. Martinez-Jimenez MC, Munoz P, ValerioM, et al. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother 2015; 70: 3107-15.
35. Martinez-Jimenez MC, Munoz P, Valerio M et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother 2015; 70: 2354-61.
36. Martinez-Jimenez MC, Munoz P, Guinea J et al. Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol 2014; 52: 270-5.
37. Guinea J, Escribano P, Marcos-Zambrano LJ et al. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Med Mycol 2016; 54: 353-60.
38. Escribano P, Rodriguez-Creixems M, Sanchez-Carrillo C et al. Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital. J Clin Microbiol 2013; 51: 2118-23.
39. Marcos-Zambrano LJ, Escribano P, Sanchez C et al. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 2014; 58: 4565-72.
40. Escribano P, Pelaez T,Munoz P et al. Is azole resistance in Aspergillus fumigatus a problemin Spain? Antimicrob Agents Chemother 2013; 57: 2815-20.
41. Munoz P, Fernandez-Turegano CP, Alcala L et al. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis 2002; 44: 163-7.
42. Munoz P, Giannella M, Fanciulli C et al. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect 2011; 17: 1538-45.
43. Pelaez T, Alvarez-Perez S, Mellado E et al. Invasive aspergillosis caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with leukaemia. J Med Microbiol 2013; 62: 474-8.
44. Munoz P, Burillo A, Bouza E. Environmental surveillance and other control measures in the prevention of nosocomial fungal infections. Clin Microbiol Infect 2001; 7 Suppl 2: 38-45.
45. Munoz P, Guinea J, Pelaez T et al. Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. Transpl Infect Dis 2004; 6: 50-4.
46. Pelaez T, Munoz P, Guinea J et al. Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis 2012; 54: e24-31.
47. Martin-Pena A, Gil-Navarro MV, Aguilar-Guisado M et al. Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia. Antimicrob Agents Chemother 2013; 57: 4664-72.
48. Barnes RA, Stocking K, Bowden S et al. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect 2013; 67: 206-14.
49. Aguado JM, Vazquez L, Fernandez-Ruiz M et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reactionbased Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015; 60: 405-14.
50. Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol 2016; 11: 103-17.
51. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60: 892-9.
52. Neely LA, Audeh M, Phung NA et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 2013; 5: 182ra54.
53. Pfaller MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol 2016; 54: 1-22.
54. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-51.
55. Baddley JW, Patel M, Jones M et al. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004; 50: 119-24.
56. Vazquez J, Reboli AC, Pappas PG et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis 2014; 14: 97.